Industry Developments

BMI View: The Czech Republic's disease and drug consumption profile illustrates a considerable gap between this market and Western Europe, suggesting that the population's demand for... 2011-07-07

BMI View: While headlines that the Russian offices of Novartis and Teva have been raided by police will be unwelcome within the industry, it is critical to recall that the raids relate... 2011-07-06

BMI View: The content and process of new legislation relating to drug and healthcare reforms in Slovakia has been strongly criticised by a leading local pharmaceutical association.... 2011-07-05

BMI View: We see Pfizer's collaboration with leading Russian non-state research complex ChemRar as a further improvement in the firm's efforts to improve its local presence, which BMI... 2011-07-01

BMI View: The issuance of government guarantees for a loan to state-owned Serbian drugmaker Galenika will ensure the continuation of medicine supplies to this market. The loan is sufficient... 2011-06-30

BMI View: While many innovative pharmaceutical firms have identified pricing policies and weaknesses in Turkey's IP framework as key challenges that will continue to deter further capital... 2011-06-29

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has declined. BMI's Pharmaceuticals & Healthcare Business Environment Ratings (BERs), which assess markets... 2011-06-28

BMI View: While the Belarusian Ministry of Health has been highly active to curb the growth of drug prices resulting from the country's currency crisis, BMI has no doubt that pharmaceutical... 2011-06-27

BMI View: Slovakia's pharmaceutical market is set for an extended period of low growth and lower prices. The legislative progression of the drug policy reform is nearing completion,... 2011-06-24

BMI View: Late-stage revisions to Poland's pharmaceutical reimbursement act have been broadly positive for pharmaceutical companies operating in this market. However, the central premise... 2011-06-23